Compare MATW & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | DSGN |
|---|---|---|
| Founded | 1850 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 819.6M |
| IPO Year | 1995 | 2021 |
| Metric | MATW | DSGN |
|---|---|---|
| Price | $28.69 | $13.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | 125.7K | ★ 469.9K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ 59.07 | N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $1,795,737,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.62 | $3.11 |
| 52 Week High | $29.11 | $17.25 |
| Indicator | MATW | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 55.22 |
| Support Level | $25.38 | $9.71 |
| Resistance Level | $29.11 | $13.54 |
| Average True Range (ATR) | 0.83 | 1.07 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 48.02 | 25.42 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.